OpenURL Connection Search

Select item for more details and to access through your institution.

Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.
Published in:
Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2021, v. 20, n. 1, p. 1, doi. 10.1016/j.aohep.2020.09.002
By:
- Peribañez-Gonzalez, Mario;
- Cheinquer, Hugo;
- Rodrigues, Lino;
- Lima, Maria Patelli;
- Reis Álvares-da-Silva, Mário;
- Madruga, José;
- Roberto Parise, Edison;
- Guimarães Pessoa, Mário;
- Furtado, Juvencio;
- Villanova, Marcia;
- Ferreira, Adalgisa;
- Mazzoleni, Felipe;
- Nascimento, Ecio;
- Faria Silva, Giovanni;
- Fredrick, Linda;
- Krishnan, Preethi;
- Burroughs, Margaret;
- Reuter, Tania
Publication type:
Article
Sinusoidal obstruction syndrome secondary the intake of Senecio brasiliensis: A case report.
Published in:
Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2021, v. 20, n. 1, p. 1, doi. 10.1016/j.aohep.2019.08.009
By:
- Alrutz Barcelos, Samantha Thifani;
- Marin Dall'Oglio, Vincent;
- de Araújo, Alexandre;
- Schmidt Cerski, Carlos Thadeu;
- Reis Álvares-da-Silva, Mário
Publication type:
Article
Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial.
Published in:
Frontiers in Nutrition, 2024, p. 1, doi. 10.3389/fnut.2024.1362694
By:
- Souza Silva-Sperb, Amanda;
- Abadie Moraes, Helena;
- Alrutz Barcelos, Samantha Thifani;
- Concheski de Moura, Bruna;
- Longo, Larisse;
- Truccolo Michalczuk, Matheus;
- Schmidt Cerski, Carlos Thadeu;
- Uribe-Cruz, Carolina;
- Reverbel da Silveira, Themis;
- Reis Álvares-da-Silva, Mário;
- Dall'Alba, Valesca
Publication type:
Article

Found: 3

Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.

Sinusoidal obstruction syndrome secondary the intake of Senecio brasiliensis: A case report.

Probiotic supplementation for 24 weeks in patients with non-alcoholic steatohepatitis: the PROBILIVER randomized clinical trial.